Involvement of microsomal fatty aldehyde dehydrogenase in the α-oxidation of phytanic acid  by Verhoeven, N.M. et al.
Involvement of microsomal fatty aldehyde dehydrogenase in the
K-oxidation of phytanic acid
N.M. Verhoevena;*, C. Jakobsa, G. Carneyb, M.P. Somersb, R.J.A. Wandersc, W.B. Rizzob
aDepartment of Clinical Chemistry, Metabolic Unit, Free University Hospital Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
bDepartments of Human Genetics and Pediatrics, Medical College of Virginia, Virginia Commonwealth University, 1101 E Marshall St Room 12-026,
Richmond, VA, USA
cDepartments of Pediatrics and Clinical Chemistry, Academic Medical Center, Meibergdreef 9, Amsterdam, The Netherlands
Received 27 April 1998
Abstract We investigated the role of microsomal fatty aldehyde
dehydrogenase (FALDH) in the conversion of pristanal into
pristanic acid. Cultured skin fibroblasts from controls and
patients with Sjoºgren-Larsson syndrome (SLS) who are geneti-
cally deficient in FALDH activity were incubated with [2,3-
3H]phytanic acid. The release of aqueous-soluble radioactivity by
the SLS cells was decreased to 25% of normal, consistent with an
intact formation of pristanal but a deficiency of further
oxidation. SLS cells also accumulated four-fold more radio-
activity in N-alkyl-phosphatidyl ethanolamine, which arises from
incorporation of free aldehyde into phosphatidyl ethanolamine.
Recombinant human FALDH expressed in Chinese hamster
ovary cells readily oxidized pristanal and cultured fibroblasts
from SLS patients showed a severe deficiency in FALDH
activity (13% of normal) when pristanal was used as substrate.
Nevertheless, SLS patients did not accumulate phytanic acid in
their plasma. We conclude that FALDH is involved in the
oxidation of pristanal to pristanic acid and that this reaction is
deficient in patients with SLS.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The human diet contains a branched chain fatty acid, phy-
tanic acid (3,7,11,15-tetramethylhexadecanoic acid), that can
be rapidly metabolized. The mechanism of this degradation is
di¡erent from the L-oxidation by which straight chain fatty
acids are degraded, as the L-methyl group in the phytanic acid
molecule blocks formation of a 3-ketoacyl-CoA intermediate.
Instead, phytanic acid is initially oxidized by K-oxidation,
shortening the chain by one carbon atom. After activation
to phytanoyl-CoA, 2-hydroxyphytanoyl-CoA is formed by
phytanoyl-CoA hydroxylase, a dioxygenase type of enzyme
using 2-ketoglutarate as cofactor [1^3]. Hereafter, 2-hydroxy-
phytanoyl-CoA is converted to pristanal and formyl-CoA [4^
6]. The enzyme that catalyzes this reaction is not known, but
probably functions as a lyase. After this decarboxylation re-
action, pristanal is oxidized to pristanic acid in a NAD(P)
dependent reaction [6,7]. Pristanic acid can, after activation,
be degraded by peroxisomal L-oxidation.
The conversion of 2-hydroxyphytanoyl-CoA to pristanic
acid was found to be localized in microsomes in human liver
[7]. This was a surprising ¢nding, as it is well known that the
¢rst step in K-oxidation, which is formation of 2-hydroxyphy-
tanoyl-CoA from phytanoyl-CoA, occurs in peroxisomes.
However, the microsomal localization of the decarboxylation
step is consistent with the normal activity of this reaction in
peroxisome de¢cient liver obtained from a patient with Zell-
weger syndrome [7].
Phytanic acid K-oxidation is impaired in three peroxisomal
disorders: classical Refsum disease, generalized peroxisomal
disorders like the Zellweger syndrome and in rhizomelic chon-
drodysplasia punctata (RCDP). In all three disorders, the ¢rst
step of K-oxidation, the conversion of phytanoyl-CoA to 2-
hydroxyphytanoyl-CoA, is de¢cient [1,8^10]. In classical Ref-
sum disease, phytanoyl-CoA hydroxylase is de¢cient due to
mutations in the gene encoding this enzyme [11,12]. In gener-
alized peroxisomal disorders, there is an absence of functional
peroxisomes, resulting in a de¢ciency of various peroxisomal
processes, among which is the phytanoyl-CoA hydroxylase
reaction [1]. In RCDP, an import defect of proteins contain-
ing a peroxisomal targeting sequence 2 results in mistargeting
and thus severe de¢ciency of phytanoyl-CoA hydroxylase [13^
15]. Patients a¡ected with classical Refsum disease, general-
ized peroxisomal disorders and RCDP accumulate phytanic
acid in blood and tissues [16].
Aldehyde dehydrogenases comprise a family of enzymes
that oxidize a variety of aliphatic and aromatic aldehydes to
their corresponding acids. Recently, a microsomal fatty alde-
hyde dehydrogenase (FALDH) was puri¢ed from human liver
[17]. This enzyme was found to be de¢cient in patients a¡ected
with Sjoºgren-Larsson syndrome (SLS), an autosomal recessive
disorder presenting with mental retardation, congenital ich-
thyosis and spastic di- and tetraplegia [17^19]. The biochem-
ical defect, an inability to oxidize speci¢c fatty aldehydes,
results in accumulation of fatty alcohol in cultured ¢broblasts
and plasma of most SLS patients [20,21].
In search for the enzyme that oxidizes pristanal to pristanic
acid, we investigated the possible role of the microsomal
FALDH in this process. Here we report that FALDH is in-
dispensable for the complete degradation of phytanic acid.
2. Materials and methods
Phytanic acid, [3-methyl-2H3]phytanic acid, pristanic acid and [2-
methyl-2H3]pristanic acid were synthesized as described previously
[22]. Pristanal was synthesized in the Free University Hospital Am-
sterdam and puri¢ed by thin layer chromatography (TLC) on silica
gel G plates using a solvent system consisting of petroleum ether/
diethyl ether (90/10). The plate was stained with rhodamine, after
which the region corresponding to the free aldehyde was scraped o¡
and eluted with hexane/benzene (3/2). [2,3-3H]Phytanic acid was syn-
thesized as described [23]. Octadecanal-modi¢ed phosphatidyl etha-
nolamine (PE) was synthesized by reacting octadecanal with PE in
the presence of NaBH3CN in methanol as described [24]. Radioactive
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octadecanal-modi¢ed PE was synthesized in a similar fashion using
[14C]octadecanal.
2.1. Cells
Cultured skin ¢broblasts were grown in Dulbecco’s modi¢ed Ea-
gle’s medium (DMEM) containing 10% fetal bovine serum, penicillin
(100 U/ml) and streptomycin (100 Wg/ml) at 37‡C in an atmosphere of
95% air/5% CO2. Human skin ¢broblasts from SLS patients were
con¢rmed to be de¢cient in FALDH activity. Cultured ¢broblasts
from patients with RCDP and classical Refsum disease were kindly
provided by A. Moser, Kennedy-Krieger Institute, Baltimore, MD.
Fibroblasts from patients with Zellweger syndrome (GM4340) were
obtained from the Human Genetic Mutant Cell Repository, Camden,
NJ. Dr. A. Zoeller, Boston University School of Medicine, kindly
provided a Chinese hamster ovary cell line (FAA-K1A) with de¢cient
FALDH activity [24]. FAA-K1A cells were routinely grown in Ham’s
F12 medium containing 5% fetal bovine serum.
2.2. Expression of recombinant human FALDH by Chinese hamster
ovary cells
A cDNA encoding the entire human FALDH protein [25] was
cloned into the mammalian expression vector pCI-neo (Promega
Corp) and was designated pCI-neo-FALDH. Vector DNA was am-
pli¢ed and puri¢ed using standard techniques.
FAA-K1A cells were seeded in 6 well dishes containing 2 ml of F12
medium per well and allowed to attach for 2 h. 3 Wg of pCI-neo-
FALDH DNA was incubated with Fugene-6 (Boehringer-Mannheim)
according to the manufacturer’s instructions and added to each well.
After 3 days the cells were harvested, washed and homogenized as
described [18].
2.3. Incubation of intact ¢broblasts with [2,3-3H]phytanic acid
Cultured skin ¢broblasts were plated in 6 well dishes in DMEM
containing 10% fetal bovine serum and penicillin/streptomycin 3 days
prior to testing. On the day prior to testing, the media were renewed.
On the day of the experiment when the cells were con£uent, the
medium was replaced by 1 ml of DMEM containing 1% fetal bovine
serum and 1.5 WCi of [2,3-3H]phytanic acid (¢nal concentration of
phytanic acid was 50 nM). After 24 h, 0.2 ml of the medium was
removed and water-soluble radioactivity was determined as described
[23]. All cell incubations were done in duplicate wells. Water-soluble
radioactivity in the media of duplicate wells varied by less than 5%.
Cell protein was determined according to Lowry et al. using replicate
dishes.
To measure the formation of radioactive aldehyde-modi¢ed PE, the
cell monolayers were washed twice with PBS and incubated with 25
mM NaBH3CN at 37‡C for 2 h as described [24] to stabilize the
aldehyde adducts. Cells were collected by scraping, pelleted by cen-
trifugation and extracted twice with 2 ml of chloroform/methanol
(1/1). The chloroform/methanol extracts were pooled, dried under
nitrogen atmosphere, dissolved in 5 ml hexane and applied to dispos-
able 3 ml silica gel columns (J.T. Baker, Philipsburg, NJ) that were
pre-equilibrated with hexane. The columns were washed with 10 ml
hexane and the radioactive N-alkyl-PE was eluted with 10 ml di-
chloromethane, dried under nitrogen and puri¢ed by TLC on a chan-
neled silica gel G plate using a solvent system consisting of chloro-
form/methanol (98/2). Synthetic N-alkyl-PE was co-chromatographed
to localize the radioactive lipid. Lipids were visualized under UV light
after spraying the plate with rhodamine G. The regions corresponding
to N-alkyl-PE (Rf = 0.8) were collected by scraping and the radioac-
tive lipid eluted twice with 5 ml of hexane/benzene (3/2). After drying
under nitrogen, the N-alkyl-PE was resuspended in 2 ml of 0.3 M
ethanolic-NaOH and hydrolyzed overnight at 90‡C. After cooling to
room temperature, 2 ml of water was added to each tube and the
[3H]N-alkyl-PE hydrolysis product was extracted twice with 2 ml hex-
ane. The pooled hexane extracts were dried under nitrogen and the
[3H]N-alkyl-PE hydrolysis product (now free of acyl-linked fatty
acids) was puri¢ed by TLC on a channeled silica gel G plate using
a solvent system consisting of hexane/ether/acetic acid (60/40/1). The
hydrolysis product of non-radioactive octadecanyl-modi¢ed PE (25
Wg) was co-chromatographed with each sample to permit visualization
by staining the plate with rhodamine and examining under UV light.
The regions corresponding to the hydrolysis product of N-alkyl-PE
(Rf = 0.45) were collected by scraping and the radioactivity was de-
termined. Using synthetic [14C]octadecanal-modi¢ed PE, the overall
recovery of the radioactive hydrolysis product of N-alkyl-PE was
71 þ 4%. The data shown in Section 3 were not corrected for recovery.
To measure incorporation of [2,3-3H]phytanic acid into PE, radio-
active phospholipids were eluted o¡ the silica gel columns (after elu-
tion of N-alkyl-PE as described above) with 10 ml of methanol and
dried under nitrogen. PE was puri¢ed by TLC [25].
2.4. Fatty aldehyde dehydrogenase activity in cultured ¢broblasts using
pristanal and octadecanal as substrates
FALDH was assayed according to Rizzo and Craft [18] as modi¢ed
by Kelson et al. [17]. Both substrates were used at 175 WM ¢nal
concentration in the assays.
2.5. Quanti¢cation of phytanic acid and pristanic acid in plasma
The concentrations of phytanic acid and pristanic acid in plasma
samples from controls and patients a¡ected with SLS were determined
by stable isotope dilution gas chromatography mass spectrometry as
previously described [16].
3. Results
3.1. Incubation of intact ¢broblasts with [2,3-3H]phytanic acid
To determine whether microsomal FALDH was involved in
the oxidation of phytanic acid, we incubated [2,3-3H]phytanic
acid with intact ¢broblasts from SLS patients, normal con-
trols and patients with defective K-oxidation. The ability of
cells to release aqueous-soluble radioactivity into the medium
was used as a measure of phytanic acid K-oxidation [23]. As
shown in Table 1, the cells from patients with SLS released
only 25% of the aqueous-soluble radioactivity compared to
normal controls, suggesting that FALDH activity is involved
in phytanic acid K-oxidation. In classical Refsum disease, the
release of radioactivity was more severely depressed to about
10% of control values. In ¢broblasts from the Zellweger pa-
tient, no activity could be detected, whereas the cells from the
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Table 1
Metabolism of [2,3-3H]phytanic acid by cultured ¢broblasts
Fibroblasts Aqueous-soluble radioactivity released
into the medium
Radioactivity incorporated
into N-alkyl-PE
Radioactivity incorporated
into PE
(cpm/h/mg cell protein) (cpm/mg cell protein) (cpm/mg cell protein)
Normal controls (n = 4)a 70 440 þ 16 690b 708 þ 614 9 640 þ 4 780
SLS (n = 4) 17 760 þ 10 190 3 084 þ 586 7 770 þ 1 260
Classical Refsum disease (n = 1) 8 160 558 26 770
Zellweger syndrome (n = 1) 0 667 5 040
RCDP (n = 1) 2 880 853 9 450
Cells were incubated for 24 h. The release of aqueous-soluble radioactivity into the medium, incorporation of radioactivity into the alkyl linkage of
N-alkyl-PE and into PE were determined as described in Section 2.
aNumber of di¡erent cell lines tested.
bMean þ standard deviation.
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RCDP patient released a small amount of radioactivity (4% of
normal).
If the impaired tritium release by SLS cells were due to a
block in pristanal oxidation, accumulation of N-alkyl-modi-
¢ed PE, which arises from Schi¡ base formation of free pris-
tanal with the ethanolamine moiety of PE, might occur [24].
We therefore measured radioactive N-alkyl-PE in the same
¢broblast cultures used to measure tritium release. As shown
in Table 1, the SLS cells accumulated four-fold more radio-
activity in N-alkyl-PE than did normal control cells. In con-
trast, incorporation of radioactivity into non-modi¢ed PE was
normal in SLS cells.
3.2. Fatty aldehyde dehydrogenase activity using pristanal as
substrate
To determine whether pristanal was a substrate for
FALDH, we used recombinant human FALDH overex-
pressed in FALDH-de¢cient Chinese hamster ovary cells
(FAA.K1A). The FALDH activity in homogenates of FAA-
K1A cells that were transfected with an expression vector
containing the human FALDH cDNA was 200^350-fold high-
er than in untransfected cells (data not shown). The recombi-
nant enzyme readily oxidized pristanal and displayed an ap-
parent Km of 40 WM. The enzyme activity with saturating
concentrations of pristanal (175 WM) and 1.5 mM NADP
was 30% of that measured with an equivalent NAD concen-
tration. FALDH activity was considerably higher (7^8-fold)
with octadecanal as substrate than with pristanal.
FALDH activity was measured in cultured skin ¢broblasts
homogenates from normal controls using pristanal and octa-
decanal as substrates. As seen with the recombinant FALDH,
the ¢broblast enzyme showed a similar apparent Km (40 WM)
with pristanal (data not shown). In addition, enzyme activity
with octadecanal was about nine-fold higher than with pris-
tanal (Table 2). FALDH activity was also assayed in SLS
¢broblasts using both substrates (Table 2). In SLS cells,
FALDH activity was severely decreased. When pristanal
was used as substrate, SLS ¢broblasts had a residual activity
of about 13% of normal. Using octadecanal as substrate, the
FALDH activity in SLS cells was about 7% of that found in
normal controls.
3.3. Quanti¢cation of phytanic acid and pristanic acid in
plasma
We wondered whether a defect in pristanal oxidation that
occurs after the decarboxylation step in K-oxidation would
lead to phytanic acid accumulation in SLS. As shown in Table
3 there were no signi¢cant di¡erences in the concentrations of
phytanic acid and pristanic acid and in the pristanic acid/phy-
tanic acid ratios in plasma from controls and patients with
SLS.
4. Discussion
To further elucidate the phytanic acid K-oxidation pathway,
we investigated the oxidation of pristanal to pristanic acid.
The nature of the substrate and the product suggested the
enzyme catalyzing this reaction would be an aldehyde dehy-
drogenase (ALDH). In man, several ALDHs are known
which di¡er in subcellular localization, amino acid sequence,
substrate speci¢city and biophysical properties. In human mi-
crosomes, FALDH oxidizes straight chain aliphatic aldehydes
of 6^24 carbons to their corresponding fatty acids [17]. This
FALDH also acts on dihydrophytal, a 20 carbon saturated
branched chain aldehyde, and other 3-methyl and 2-methyl
branched-chain aliphatic substrates (Rizzo, unpublished). Ac-
tivity of this enzyme is de¢cient in SLS, resulting in impaired
fatty alcohol oxidation [18,21].
Our results imply FALDH is involved in the conversion of
pristanal into pristanic acid. In intact SLS ¢broblasts, the
release of radioactivity from [2,3-3H]phytanic acid was about
25% of the values found in controls. With normal phytanic
acid oxidation, the release of tritium label is expected to be
25% during the formation of 2-hydroxyphytanoyl-CoA from
phytanoyl-CoA. The conversion of 2-hydroxyphytanoyl-CoA
to pristanal is not expected to release additional label, whereas
subsequent formation of pristanic acid from pristanal would
release another 25% of the label. Further L-oxidation of pris-
tanic acid liberates the remainder of the label in propionyl-
CoA. The observation that in SLS cells the tritium release is
only 25% of the values in controls points to an intact forma-
tion of 2-hydroxyphytanoyl-CoA but de¢cient oxidation of
pristanal. In the ¢broblasts from patients a¡ected with classi-
cal Refsum disease, Zellweger syndrome and RCDP, the tri-
tium release was 10% or lower. This is consistent with the
¢ndings of Jansen et al. and Verhoeven et al. that the dioxy-
genase which converts phytanoyl-CoA into 2-hydroxyphyta-
noyl-CoA is de¢cient in these disorders [1,8^10].
The results reported here are in accordance with our pre-
vious ¢ndings that formation of pristanic acid from 2-hy-
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Table 3
Concentrations of phytanic acid and pristanic acid in plasma from normal controls and patients a¡ected with SLS
Phytanic acid (WM) Pristanic acid (WM) Pristanic/Phytanic
Controls (n = 90) 0.04^9.88 0.01^2.98 0.05^0.40
SLS patients (n = 10) 0.45^8.86 0.06^2.88 0.09^0.18
Table 2
Fatty aldehyde dehydrogenase activity in cultured ¢broblast homogenates using pristanal and octadecanal as substrates
Cells FALDH activity (pmol/min/mg protein)
Pristanal Octadecanal
Normal controls (n = 6)a 916 þ 203 8351 þ 2105
SLS (n = 9) 116 þ 92 569 þ 275
% of mean normal FALDH activity in SLS cells 13 7
Enzyme assays were performed with 1.5 mM NAD.
aNumber of di¡erent cell lines tested.
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droxyphytanoyl-CoA is localized in microsomes in human
liver, and that the enzyme catalyzing the conversion of pris-
tanal to pristanic acid uses NAD and/or NADP as cofac-
tors [7]. The impaired release of aqueous soluble radioactivity
from [2,3-3H]phytanic acid and the accumulation of radioac-
tive N-alkyl-PE by SLS ¢broblasts strongly support the in-
volvement of FALDH in phytanic acid oxidation. This con-
clusion is further supported by the demonstration that
recombinant FALDH utilizes pristanal as substrate and
FALDH activity using pristanal is de¢cient in SLS cells.
Our results argue against a signi¢cant contribution by an
alternative ALDH enzyme catalyzing the oxidation of prista-
nal. However, Croes et al. [6] have recently reported that rat
liver peroxisomes are capable of oxidizing 2-methyl-pentade-
canal to 2-methyl-pentadecanoic acid in the presence of
NAD. It is unclear whether this activity is speci¢c to rodents
or is physiologically relevant to phytanic acid oxidation. If
this peroxisomal activity is present in humans, our results
suggest that it makes a minor contribution to overall pristanal
oxidation.
Two transcripts from the FALDH gene have been found to
arise from alternate splicing [26]. The major transcript (which
was expressed in the FAA-K1A cells) encodes a protein with a
microsomal targeting sequence at the carboxy terminal region.
A minor transcript, accounting for less than 10% of the major
transcript, encodes a protein containing most of the micro-
somal targeting sequence but possessing an additional car-
boxy-terminal sequence of unknown function. This FALDH
protein lacks any known peroxisomal targeting sequence.
Moreover, it is unlikely that this minor FALDH isoform is
directed to peroxisomes, since no FALDH enzyme activity
was found in human liver peroxisomes.
Patients with SLS do not accumulate phytanic acid in their
plasma. This may be due to several reasons. First, it is possi-
ble that the residual activity of FALDH is su⁄cient to avoid
accumulation of phytanic acid. The residual enzyme activity
measured in whole cell homogenates (approximately 6% of
normal) is due to other ALDH enzymes [18,27]. Another fatty
aldehyde dehydrogenase, such as a cytosolic or mitochondrial
isozyme may partially take over the role of the de¢cient
FALDH in certain tissues. The normal concentrations of pris-
tanic acid and the normal ratio between pristanic acid and
phytanic acid are consistent with this explanation. Second,
the impaired pristanal oxidation in SLS may result in diver-
sion of this aldehyde intermediate into other metabolites,
thereby mitigating pristanal and phytanic acid accumulation.
Aldehydes are very reactive molecules that form Schi¡ bases
with amino groups of proteins and lipids. Recently, SLS ¢-
broblasts were shown to accumulate fatty-aldehyde-modi¢ed
PE [24], and our results demonstrate accumulation of alde-
hyde modi¢ed PE derived from phytanic acid metabolism. It
is therefore possible that SLS patients divert pristanal into
other amino-containing molecules such as proteins.
Future experiments will focus on the elucidation of the
mechanism that is responsible for the absence of phytanic
acid accumulation in SLS, and the mechanism by which the
K-oxidation intermediates are transported from one organelle
to another.
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